ABSTRACT: Neurotransmitter replacement therapy in Alzheimer's Disease is currently being attempted using bethanechol chloride (Urecholine) infused intracerebroventricularly with an Infusaid continuous infusion pump. The rationale of this therapy is based on the severe cortical pre-synaptic cholinergic deficit in the presence of relatively normal post-synaptic muscarinic receptor density. Patients are selected on the basis of strict clinical criteria at a functional stage 4 or 5 of Reisberg. A cortical biopsy at the time of pump and catheter implantation confirms the diagnosis by histological and biochemical examination. Pre-operative, post-operative and serial mental status assessments combined with functional ADL assessments monitor changes in behavior. A 6 months double-blind treatment period is done in every patient, who is then free to continue if he has improved on active treatment. This specific study is part of a multi-centre trial. Other therapeutic trials using somatostatin analogs, such as Sandostatin, could then be done. The biological effects of the latter compound are being studied currently in adult Green Vervet monkeys, prior to its use in Alzheimer patients. Furthermore autoradiography of bethanechol and peptides labeled with l4 C administered in these animals by intracerebroventricular infusion will allow a better knowledge of their pharmacological site of action. RESUME: Rapport interimaire sur le traitement substitutif par neuromediateur dans la maladie d'Alzheimer au moyen d'infusions intracerebroventriculaires de substances agonistes des chemorecepteurs. Des tentatives de traitement substitutif par neuromediateur dans la maladie d'Alzheimer sont actuellement en cours au moyen d'une pompe a infusion continue de type "Infusaid" injectant du chlorure de bethanecol (Urecholine) au niveau du systeme ventriculaire cerebral. Cette theYapie est basee sur l'observation d'un deficit cholinergique severe au niveau pre-synaptique dans le cortex alors que la densite des recepteurs muscariniques au niveau post-synaptique est relativement normale. Les patients sont chosis a l'aide de critere cliniques rigoureux alors qu'ils sont a un stade fonctionnel 4 ou 5 a l'echelle de Reisberg. Le diagnostic est confirme par un examen histologique et biochimique de tissu cerebral preleve par biopsie au moment de la mise en place du catheter et de la pompe a infusion. Des evaluations de l'6tat mental en periode pr6-op6ratoire, post-operatoire et a intervalles fixes par la suite, associees a des evaluations fonctionnelles de type "ADL" sont utilisees pour surveiller les changements de comportement des sujets. Chaque patient est soumis a une periode de traitement en double-insu de 6 mois; il(elle) est ensuite libre de continuer s'il y a eu amelioration de son etat pendant la periode de traitement actif. Notre etude fait partie d'un programme d'essais therapeutiques multi-centres. D'autres essais therapeutiques avec des analogues de la somatostatine, tel que le "Sandostatin", pourront ensuite etre faits. Les effets biologiques de cette derniere substance sont presentement a l'6tude chez les singes "Green Vervet'', avant son essai chez les patients atteints de la maladie d'Alzheimer. De plus, des etudes autoradiographiques faites a l'aide de bethanechol et de peptides marques au 14 C administres par infusion intracer6broventriculaire a ces animaux nous permettront de mieux connaitre leur site d'action pharmacologique.
LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES
Specific neurotransmitter systems are altered in patients with Alzheimer's disease. These include the cholinergic system originating from the Nucleus Basalis of Meynert and innervating large areas of the cerebral neocortex' and somatostatincontaining cortical neurons. 2 There is lesser and variable involvement of serotonin, 3 noradrenaline 4 and possibly corticotropin-releasing factoid-containing neurons.
Until the genetic basis for the expression of Alzheimer's disease is known and controlled by molecular pharmacology, or until embryonic cells can be implanted successfully, pharmacological neurotransmitter replacement therapy will continue to be of interest in the management of this condition.
Treatment using dietary precursors such as choline 6 and lecithin, 7 physostigmine 8 and more recently direct muscarinic agonists such as bethanechol 9 has been attempted. These agents were administered orally or subcutaneously, with little clinical response. Harbaugh et al in 1984 10 demonstrated the feasibility of continuous intracerebroventricular (IC V) infusion of bethanechol chloride using a subcutaneously implanted pump (Intermedics Infusaid Inc.) connected to a ventricular catheter. This avoids extracerebral muscarinic side effects and allows titration of the daily dose infused. Extrapyramidal rigidity and nausea were noted in some patients but both were reversible with alterations of the dose. Our group joined a multi-centre study to evaluate ICV infusion of bethanechol in a large number of Alzheimer patients in a double-blind cross-over study over a six month period. We report here the base-line clinical, functional and laboratory data on our nine patients, who will complete their treatment protocol in November 1986.
Patient Selection
Inclusion criterias selected patients with a clinical diagnosis of "probable Alzheimer's disease" ".intermediate stage, living with an adult who could observe and report changes in activities of daily living. Informed consent was obtained from patients and closest relatives. Table 1 summarizes the clinical features of our nine patients. All had onset of symptoms prior to age 65 and they are of mixed ethnic, educational and geographical origin. A positive family history of dementia (without autopsy confirmation) was obtained in half of the patients.
Functional Aspects
Functional independence levels were measured at the onset of the study using the Instrumental Activities of Daily Living Scale 14 and the Rapid Disability Rating Scale. 15 Testing using the first scale reveals that 7 out of 9 patients cannot dial the telephone, 6 out of 7 need to be supervised for shopping, 4 out of 4 cannot prepare meals anymore, all must be accompanied outside the home and none can handle their own finances. Thus most subjects are dependent for adaptive tasks that they previously performed well. The data from the second scale is presented in Table 2 . Here again adaptive tasks (telephone, money) are accomplished with difficulty. Dressing and grooming are the most affected skills followed by bathing. Total scores range from 11 to 15 and are congruent with the Global Deterioration Scale. ' 3 Assessments using these scales are repeated at six weeks and at three and six months following surgery.
Neuropsychological Testing
The Mini Mental State 12 is used to screen individuals, aiming at a performance between 10 and 24 on a scale of 30, and is quite reproducible. The battery of cognitive tests chosen by the multi-centre trial group are as follows: (1) the digit symbol from WAIS, Boston naming, word fluency and selective word reminding are used every three weeks; (2) block design and digit span from WAIS, Weschler memory scale, trials A and B are administered preoperatively then six weeks, three months and six months postoperatively. The results of these tests will be reported by the multi-centre trial group at the end of the study.
Laboratory Work-Up
Beyond the usual laboratory work-up required to exclude other causes of dementia, we paid special interest to the EEG, CT and MRI because of their potential use in the diagnosis of Alzheimer's disease. As we reported recently 16 and as our current data shows ( 
Pump and Catheter Implantation
The procedure is performed following endotracheal intubation and induction of general anesthesia. The patient is placed in the supine position with the head turned to the left. The scalp, neck, trunk and abdomen are shaved and disinfected using Hibitane solution (Ayerst), iodine and alcohol.
A 10 cm curvilinear incision is made over the right frontal area, behind the hairline, extending just lateral to the midline. Bleeding is controlled by diathermy and by mechanical clips applied to the scalp edges. The skin flap is retracted to expose the periosteum. A burr hole is placed 3 centimetres from the midline, 2 centimetres in front of the coronal suture. A small trephine craniotomy is performed, incorporating the burr hole at its medial edge. Bleeding from the middle table of the skull is controlled by the application of bone wax. A ventricular drain measuring 5-6 centimetres in length is inserted into the frontal horn of the right lateral ventricle. The ventricular drain is connected to a reservoir without valve. The dura is then opened in a cruciate fashion and a 1.5 to 2 centimetre square biopsy of the pre-frontal cortex is obtained. Bleeding is controlled using bipolar diathermy, oxidized regenerated cellulose and absorbable gelatin sponges. Attention is then given to the right lower quadrant of the abdomen where an 8 centimetre horizontal incision is made just below the level of the umbilicus. The incision is extended through the subcutaneous fat and the subcutaneous tissue is undermined to form a pocket that snugly accommodates the pump. The two operative sites are joined by a subcutaneous tunnel through which the tubing emanating from the pump is passed and connected to the reservoir. Prior to the final connection of the pump tubing to the reservoir, normal saline is injected into the side port of the pump to verify that the system is patent. The bone flap is returned into place and held by stainless steel wires. The galea is closed using * Rapid Disability Rating Scale -11 of Linn and Linn, 1982 (I = no assistance required, 4 = completely dependent) ** G.D.S. = Global Deterioration Scale of Reisberg, 1982 (1 = normal, 7 = severely abnormal) absorbable suture material and the scalp is closed with 4.0 nylon. The abdominal incision is similarly closed. Bacitracin is infiltrated into both wounds, dry dressings are applied, and the patient is brought to the Recovery Room.
Moderate to severe cortical atrophy was observed in all patients. Cerebral amyloid angiopathy was evident at the time of cortical biopsy and was confirmed histologically (Figure 2 ). Relatively difficult hemostasis occurred frequently due to poorly contractile arterial vessels in which the contractile elements have been replaced by amyloid. 17 However, with meticulous diathermy and with the application of oxidative reconstituted cellulose and small pieces of absorbable gelatin sponges postoperative hemorrhage has not been encountered.
The patients are mobilized as soon as possible. The dressings are changed at 24 hours and every two days subsequently. The sutures are removed between the seventh and ninth day depending upon the quality of wound healing. Corticosteroids are not routinely used. Post-operative CT scans and x-rays of the skull, chest and abdomen are obtained to verify proper positioning of the system (Figure 3a, 3b) .
Some patients undergoing surgery have had evidence of pneumocephalus in the postoperative phase. This results from collapse of the brain at the time of dural opening and is directly related to the degree of cerebral atrophy present. Generally, this is of no clinical importance. However, the procedure had to be aborted on one occasion because of this occurrence; another patient was kept on bed rest post-operatively while awaiting brain re-expansion.
Cortical Biopsies
The cortex was dissected from white matter immediately after resection. Cortical fragments were snap frozen and stored (Table 4) showed the former to be a significantly more sensitive preparation for morphometry. Using data obtained from modified Bielschowsky stains in those patients histologically diagnosed as "definite Alzheimer", the NFT index provided a significant correlation with Mini Mental state scores (r = 0.8507), however, the SP index showed no significant correlation (r = 0.3362; Figure 4a ). This correlation is still significant for the NFT index (r = 0.8570; Figure 4b ) if two sub-diagnostic patients with low cortical Ch AT values are added in the calculations. Significant correlations of NFT and SP indexes could be established with the duration of clinical symptoms as determined by the date of onset of neurological abnormalities (r = 0.7530; r = 0.4764, Figure 5 ). Semi-quantitative estimates of neuropil NFT indexes, ultrastructural intrasynaptic involvement by NFT's ( Figure 6 ) and paired neurofilament densities were markedly increased in all patients included in the histopathological "definite Alzheimer" group. All patients fulfilling histopathological criteria for Alzheimer's disease displayed mild to moderate amounts of neuronal loss which predominated in laminae 2 and 3 and conspicuous intravascular deposits of amyloid (Figure 2) .
LE JOURNAL CANADIEN DES SCIENCES NEUROLOG1QUES
Two patients who displayed significantly decreased cortical ChAT values without significant increases of NFT and SPindexes showed high densities of intraneuritic straight neurofilaments with very few paired helical filamentous profiles (Figure 7) . One (A.K.) actually displayed 24 nm wide microtubular arrays in few cortical neurones (Figure 8 ). One patient (W.H.) could not be reliably classified within any specific diagnostic group in view of the lack of significant changes observed in both biochemical and morphometric parameters, except for increased intraneuritic straight neurofilaments on electron microscopic examination. Except for this patient, all ChAT values were as low as those obtained from post-mortem material. Muscarinic binding was heterogenous among patients and will need to be correlated with the clinical response to bethanechol infusion at the end of the study. The correlation between the NFT index vs muscarinic binding was very strong (r = 0.9150), but was weaker with the SP index (r = 0.4878; Figure 9 ).
Clinical Course
All patients were admitted at the Montreal Neurological Institute for their surgery, many sharing their rooms with a relative. This lessened the incidence of pre-and post-operative confusion. In those nine patients there was only one focal seizure on day 5 post op, treated with phenytoin. No hemor- rhage occurred despite the congophilic angiopathy seen on biopsy. The Infusaid pump model 400 is refilled every three weeks by trans-cutaneous puncture at which time neuropsychological tests and functional assessments are made. Transient nausea occurs in some patients after pump refill. Some families are spontaneously looking for stimulation strategies such as children's books and illustrated dictionaries.
DISCUSSION
The morphological and morphometric data gathered in our study differ from those of Neary et al 19 who, in a large series of demented patients submitted to temporal lobe biopsy, showed weak correlations of neuronal loss and NFT indexes with deterioration of cognitive function as determined by the Mini Mental State. Two of our patients did not fulfill histopathological criteria for inclusion within the "definite Alzheimer'' group. They nonetheless had significantly decreased cortical ChAT values. In the "definite" cases, NFT and SP indexes could be correlated with duration of symptoms ( Figure 5 ). Our data thus suggests that the rate of Alzheimerization, particularly as determined by the NFT index, varies markedly from patient to patient. In this context, the onset of pre-frontal cortex morphological stigmata would represent a late manifestation of Alzheimer's disease. This is consistent with Positron Emission Tomography (PET) data showing a predominance of fluorodeoxyglucose hypometabolism in the parietal cortex in the early phase of Alzheimer's disease. 20 We therefore suspect that patients receiving bethanechol infusion who will benefit the least are those with low Mini 
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Mental State score and high NFT indexes, since these abnormalities are correlated with a high incidence of intrasynapticpaired helical filaments and low muscarinic binding. Conversely, patients with a sub-diagnostic threshold NFT index and a high incidence of intraneuritic straight neurofilaments may benefit from bethanechol infusion.
For those who will fail to improve on bethanechol infusion somatostatin replacement therapy may be an alternative. Somatostatin (SRIH) receptors have been well described within human cortex 21 and SRIH concentrations are low in the CSF 22 and in the frontal and temporal cortex 2324 of patients with Alzheimer's disease. The functional role of this transmitter is not yet clear, 25 but loss of SRIH in the parietal cortex has been correlated tofluoro-deoxyglucosehypometabolism. 26 The presence of paired helical filaments in SRIH positive cell bodies implicates these neurons in the primary disease process. 2 Early attempts to intravenously replace SRIH using an analog have failed. 27 We are exploring the feasibility of continuous cisterna magna infusion of the SRIH analog Sandostatin R by testing its stability in the Infusaid pump and by documenting the presence or absence of behavioral and metabolic toxicity in the monkey. SRIH has already been infused safely in man via the spinal intrathecal route for control of intractable pain. 28 There is thus a realistic hope of testing its therapeutic value in Alzheimer's disease in the near future. 
CONCLUSION
There is cautious optimism that transmitter replacement therapy using ICV infusion may be feasible and useful in Alzheimer's disease. It is already clear that cortical biopsy is essential to the basic understanding of the disease and may be useful in predicting drug response.
